C3J Therapeutics Bolsters Antimicrobial R&D Program; Acquires Engineered Bacteriophage Assets from Synthetic … – Business Wire (press release)
C3J Therapeutics Bolsters Antimicrobial R&D Program; Acquires Engineered Bacteriophage Assets from Synthetic …Business Wire (press release)LOS ANGELES & LA JOLLA, Calif.–(BUSINESS WIRE)–C3J Therapeutics, Inc., (C3J) a private biotechnology … Continue reading
